SEC Filings

Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

Filing date	Form	Description	View
Dec 30, 2021	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-21-154482.pdf 0001104659-21-154482.rtf 0001104659-21-154482.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Dec 23, 2021	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-21-153200.pdf 0001104659-21-153200.rtf 0001104659-21-153200.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Dec 17, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-011105.pdf 0001179110-21-011105.rtf 0001179110-21-011105.xls
Dec 15, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-010988.pdf 0001179110-21-010988.rtf 0001179110-21-010988.xls
Dec 10, 2021	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-21-148281.pdf 0001104659-21-148281.rtf 0001104659-21-148281.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Dec 10, 2021	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001179110-21-010825.pdf 0001179110-21-010825.rtf 0001179110-21-010825.xls
Dec 10, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-010826.pdf 0001179110-21-010826.rtf 0001179110-21-010826.xls
Dec 09, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-010721.pdf 0001179110-21-010721.rtf 0001179110-21-010721.xls
Nov 29, 2021	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-21-144087.pdf 0001104659-21-144087.rtf 0001104659-21-144087.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Nov 18, 2021	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-010240.pdf 0001179110-21-010240.rtf 0001179110-21-010240.xls

Investors & Media

Transformative science, targeted medicines

SEC Filings

Pagination